Pitt Shield

Ultrasound-sensitive nanodroplets achieve targeted neuromodulation.

Authors: Lea-Banks H, Meng Y, Wu SK, Belhadjhamida R, Hamani C, Hynynen K

Focused ultrasound (FUS) offers an attractive tool for non-invasive neuromodulation, addressing a clinical need to develop more minimally invasive approaches that are safer, more tolerable and versatile. In combination with a cavitation agent, the effects of ultrasound can be amplified and localized for therapy. Using c-Fos expression mapping, we show how ultrasound-sensitive nanodroplets can be used to induce either neurosuppression or neurostimulation, without disrupting the blood-brain barrier in rats. By repurposing a commercial ultrasound contrast agent, Definity, lipid-shell decafluorobutane-core nanodroplets of 212.5 ± 2.0 nm were fabricated and loaded with or without pentobarbital. FUS was delivered with an atlas-based targeting system at 1.66 MHz to the motor cortex of rats, using a feedback-controller to detect successful nanodroplet vaporization and drug release. Neuromodulation was quantified through changes in sensorimotor function and c-Fos expression. Following FUS-triggered delivery, sham nanodroplets induced a 22.6 ± 21% increase in local c-Fos expression, whereas pentobarbital-loaded nanodroplets induced a 21.7 ± 13% decrease (n = 6). Nanodroplets, combined with FUS, offer an adaptable tool for neuromodulation, through local delivery of small molecule anesthetics or targeted mechanical effects.

Introduction

Purpose Drug delivery WITHOUT BBB opening
Study Objective To determine whether ultrasound-sensitive nanodroplets combined with focused ultrasound can produce localized neurostimulation or neurosuppression in rat motor cortex—via mechanical effects or targeted pentobarbital delivery—without disrupting the blood–brain barrier.
Animal model / Human subject Rat (Rattus norvegicus), strain None, age None, sex None
Disease model Healthy
MRI or image guidance method Atlas-based targeting system
Targeted brain region(s) Motor Cortex
Cargo name and characteristics Pentobarbital — small-molecule anesthetic loaded into lipid-shell decafluorobutane-core nanodroplets (nanoparticle carrier; ~212.5 ± 2.0 nm)

Outcomes and Safety

Summary of Outcomes Atlas-targeted FUS at 1.66 MHz with feedback-controlled vaporization of 212.5 nm lipid-shell decafluorobutane nanodroplets produced bidirectional neuromodulation without BBB disruption: sham (no drug) droplets + FUS increased local c-Fos (~+22.6%) indicating neurostimulation, while pentobarbital-loaded droplets + FUS decreased c-Fos (~−21.7%) indicating neurosuppression.
Safety-related matter The study reports neuromodulation achieved without disrupting the blood–brain barrier in rats. No adverse effects or safety concerns are reported.

Brain Region

Ultrasound Parameters

FUS Frequency 1.66 MHz
Focal Characteristics focal depth: None; focal length: None; aperture size: None
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search